This is supported by the fact that TMB-high patients were enriched in both favorable mutations such as MUC4 and TP53 as well as adverse mutations such as LRP1B and COL11A1. Furthermore, TMB-high patients had increased immune-ratios of infiltrating CD4 T-cells, Tregs and B-cells; yet CD8 T-cells, the most critical anti-tumor immune subset, were markedly reduced. This evidence concerns the gene LRP1B and neoplasm.